

Matthias W Beckmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435033/publications.pdf>

Version: 2024-02-01

154
papers

8,153
citations

94433

37
h-index

53230

85
g-index

166
all docs

166
docs citations

166
times ranked

12216
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2022, 164, 68-75.	1.4	12
2	OUP accepted manuscript. <i>Human Molecular Genetics</i> , 2022, , .	2.9	1
3	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnancy and at birth in Franconia). <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 226-234.	1.8	6
4	Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study. <i>JMIR Formative Research</i> , 2022, 6, e33635.	1.4	19
5	MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 1721.	3.7	5
6	Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1298-1308.	3.7	4
7	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	2.8	1
8	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	7.0	3
9	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Care</i> , 2021, 16, 254-262.	1.4	0
10	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021, 16, 291-298.	1.4	2
11	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 521-531.	1.7	13
12	Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 967-980.	1.7	11
13	The association between prenatal alcohol consumption and preschool child stress system disturbance. <i>Developmental Psychobiology</i> , 2021, 63, 687-697.	1.6	10
14	Genetic variants in the glucocorticoid pathway genes and birth weight. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 427-434.	1.7	1
15	Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. <i>Brain Sciences</i> , 2021, 11, 154.	2.3	7
16	Active Participation, Mind-Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199010.	2.0	1
17	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
18	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. <i>Breast Care</i> , 2021, 16, 1-9.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Endogenous Retroviral K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657187.	2.8	16
20	Association of genomic variants at <i>PAX8</i> and <i>PBX2</i> with cervical cancer risk. <i>International Journal of Cancer</i> , 2021, 149, 893-900.	5.1	7
21	Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 699-707.	1.8	9
22	Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7920.	2.6	6
23	Complementary and alternative medicine (CAM) in women with endometriosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 262, 7-12.	1.1	3
24	Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. <i>Reproductive BioMedicine Online</i> , 2021, 43, 788-798.	2.4	2
25	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	1.7	2
26	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
27	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	2.2	13
28	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. <i>Cancers</i> , 2021, 13, 5577.	3.7	5
29	Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 795580.	4.8	3
30	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 289-294.	1.7	5
31	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793.	3.2	9
32	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750.	3.3	15
33	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	3.7	6
34	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	1.8	4
35	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	2.6	1
36	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020, 20, 86.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Me2SO perfusion time for whole-organ cryopreservation can be shortened: Results of micro-computed tomography monitoring during Me2SO perfusion of rat hearts. PLoS ONE, 2020, 15, e0238519.	2.5	7
38	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast, 2020, 54, 88-95.	2.2	34
39	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Research and Treatment, 2020, 184, 311-324.	2.5	10
40	Introducing multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology. Archives of Gynecology and Obstetrics, 2020, 302, 1401-1406.	1.7	7
41	Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance. Journal of Clinical Medicine, 2020, 9, 4033.	2.4	1
42	Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?. International Journal of Molecular Sciences, 2020, 21, 8238.	4.1	12
43	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer – results from the randomized phase III SUCCESS-A trial. Breast Cancer Research, 2020, 22, 111.	5.0	15
44	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
45	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. Complementary Medicine Research, 2020, 27, 431-439.	1.2	3
46	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. Scientific Reports, 2020, 10, 5171.	3.3	5
47	Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer. Cancers, 2020, 12, 446.	3.7	13
48	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. International Journal of Cancer, 2020, 147, 2458-2468.	5.1	12
49	The safety and satisfaction of ovarian tissue cryopreservation in prepubertal and adolescent girls. Reproductive BioMedicine Online, 2020, 40, 547-554.	2.4	16
50	Feasibility of internal inguinoperitoneal drainage after inguinofemoral lymphadenectomy in vulvar cancer. Archives of Gynecology and Obstetrics, 2020, 301, 1513-1519.	1.7	1
51	Collective forces of tumor spheroids in three-dimensional biopolymer networks. ELife, 2020, 9, .	6.0	35
52	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.. Journal of Clinical Oncology, 2020, 38, e12647-e12647.	1.6	0
53	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2019, 143, 206-211.	2.5	18
54	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertility and Sterility, 2019, 112, 731-739.e1.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Ovarian Tissue Transplantation: Experience From Germany and Worldwide Efficacy. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986735.	3.9	62
56	Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. <i>European Journal of Medical Research</i> , 2019, 24, 32.	2.2	6
57	Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. <i>Breast</i> , 2019, 44, 81-89.	2.2	8
58	Comparison of preoperative and postoperative sexual function in patients with deeply infiltrating endometriosis with and without bowel resection. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 239, 21-29.	1.1	8
59	Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 63-71.	1.8	1
60	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	2.5	35
61	Electrospun patterned porous scaffolds for the support of ovarian follicles growth: a feasibility study. <i>Scientific Reports</i> , 2019, 9, 1150.	3.3	48
62	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. <i>Breast Care</i> , 2019, 14, 41-47.	1.4	5
63	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
64	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
65	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
66	Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. <i>Early Human Development</i> , 2018, 119, 1-7.	1.8	18
67	Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. <i>New England Journal of Medicine</i> , 2018, 378, 1604-1610.	27.0	113
68	Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
69	Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 789-796.	2.8	42
70	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 219-229.	3.0	3
71	Breast cancer patients'™ satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 147-156.	1.7	7
72	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	2.6	30

#	ARTICLE	IF	CITATIONS
73	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	2.5	56
74	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018, 18, 175-183.	2.4	21
75	Update Breast Cancer 2018 (Part 2) â€“ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
76	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018, 59, 1406-1413.	1.1	10
77	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€“ Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
78	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
79	Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue. <i>Reproductive BioMedicine Online</i> , 2018, 36, 188-196.	2.4	47
80	Supportive Infusions in Integrative Breast and Gynecological Oncology â€“ Report on Patientsâ€™ Satisfaction and Self-reported Effects and Side Effects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1129-1137.	1.8	1
81	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. <i>BMC Cancer</i> , 2018, 18, 926.	2.6	16
82	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	2.6	59
83	Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial. <i>BMC Cancer</i> , 2018, 18, 886.	2.6	48
84	Major and minor complications after resection without bowel resection for deeply infiltrating endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 991-999.	1.7	10
85	Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 889-895.	1.7	28
86	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	3.5	21
87	Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2018, 17, 941-951.	2.0	9
88	Comparison of dienogest and progesterone effects on uterine contractility in the extracorporeal perfusion model of swine uteri. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1293-1299.	2.8	2
89	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
90	Total laparoscopic hysterectomy: how does training for surgeons in a standardized operation affect hospitals and patients?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 763-771.	1.7	1

#	ARTICLE	IF	CITATIONS
91	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	1.8	3
92	Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017, 145, 142-147.	1.4	24
93	Gynecologic oncologists'™ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 295-301.	1.7	24
94	Major and minor complications after anterior rectal resection for deeply infiltrating endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1277-1285.	1.7	19
95	Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). <i>Journal of Surgical Oncology</i> , 2017, 115, 238-242.	1.7	12
96	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
97	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
98	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
99	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678.	1.8	21
100	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. <i>International Journal of Cancer</i> , 2017, 140, 95-102.	5.1	99
101	Repetitive Maturation of Oocytes From Non-Stimulated Xenografted Ovarian Tissue From a Prepubertal Patient Indicating the Independence of Human Ovarian Tissue. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1304-1311.	1.8	7
102	Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19
103	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017, 22, 30.	2.2	6
104	Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society. <i>BMC Cancer</i> , 2017, 17, 850.	2.6	68
105	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016, 11, 315-322.	1.4	6
106	CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. <i>Tumor Biology</i> , 2016, 37, 13769-13775.	1.8	8
107	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016, 139, 1967-1974.	5.1	19
108	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27

#	ARTICLE	IF	CITATIONS
109	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Archives of Gynecology and Obstetrics, 2016, 294, 343-351.	1.7	21
110	Ovarian tissue cryopreservation and retransplantation – what do patients think about it?. Reproductive BioMedicine Online, 2016, 32, 394-400.	2.4	21
111	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
112	Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case-control study. BMC Cancer, 2015, 15, 751.	2.6	25
113	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
114	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. International Journal of Cancer, 2015, 137, 2981-2988.	5.1	31
115	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
116	Long-Term Endurance Exercise in Humans Stimulates Cell Fusion of Myoblasts along with Fusogenic Endogenous Retroviral Genes In Vivo. PLoS ONE, 2015, 10, e0132099.	2.5	37
117	Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. Fertility and Sterility, 2015, 103, 462-468.	1.0	130
118	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
119	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
120	Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Annals of Diagnostic Pathology, 2015, 19, 198-202.	1.3	102
121	Xenotransplantation of cryopreserved human ovarian tissue – a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment. Fertility and Sterility, 2015, 103, 1557-1565.	1.0	35
122	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587.	2.6	19
123	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Research, 2015, 17, 129.	5.0	93
124	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
125	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Research and Treatment, 2014, 148, 143-151.	2.5	45
126	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39

#	ARTICLE	IF	CITATIONS
127	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	493
128	Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	38
129	Meconium Indicators of Maternal Alcohol Abuse during Pregnancy and Association with Patient Characteristics. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	27
130	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
131	Preliminary observations on whole-ovary xenotransplantation as an experimental model for fertility preservation. <i>Reproductive BioMedicine Online</i> , 2014, 29, 621-626.	2.4	14
132	Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human ovarian tissue xenografted into severe combined immunodeficient mice?. <i>Fertility and Sterility</i> , 2014, 101, 1477-1484.e3.	1.0	13
133	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14.	1.4	55
134	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
135	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
136	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
137	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960
138	Economic Constraints - the Growing Challenge for Western Breast Cancer Centers. <i>Breast Care</i> , 2013, 8, 41-47.	1.4	4
139	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	2.5	22
140	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	1.3	28
141	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
142	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
143	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	21.4	256
144	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	2.5	32

#	ARTICLE	IF	CITATIONS
145	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141
146	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	21.4	235
147	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
148	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	21.4	309
149	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	21.4	276
150	Review. Fertility preservation for young female cancer patients. <i>In Vivo</i> , 2009, 23, 123-30.	1.3	34
151	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98.	2.5	77
152	Course of Ovarian Hyperstimulation Syndrome in 19 Intact Twin Pregnancies After Assisted Reproduction Techniques, With a Case Report of Severe Thromboembolism. <i>Twin Research and Human Genetics</i> , 2006, 9, 691-696.	0.6	11
153	The G20210A Prothrombin Gene Mutation and the Plasminogen Activator Inhibitor (PAI) 844GG Genotype Increase the Risk of Premature Onset of Severe Preeclampsia.. <i>Blood</i> , 2004, 104, 1050-1050.	1.4	0
154	Aspects of molecular diagnostics and therapy in obstetrics and gynecology. <i>Expert Review of Molecular Diagnostics</i> , 2003, 3, 279-287.	3.1	5